ANP-231

ANP-231 is a preclinical-stage small molecule drug candidate being developed by AlphaNavi Pharma for the treatment of pain. It is described as a next-generation inhibitor of the voltage-gated sodium channel Nav1.7 (encoded by the SCN9A gene). AlphaNavi Pharma, a spin-off from Mitsubishi Tanabe Pharma, focuses on developing selective Nav1.7 inhibitors to treat neuropathic pain conditions while avoiding the side effects associated with non-selective sodium channel blockers. ANP-231 serves as a follow-on or backup compound to the company's lead clinical asset, ANP-230, and is designed to provide improved potency or selectivity in modulating ion channel activity for analgesic purposes.